

| Study | ClinicalTrials.gov Identifier | Official title                                                                                                                                                                        | Date                  | Country     | Design                                                                                            | No. of patients | Conditions                                                                                                                                 | Intervention                                                                                                     |                  | Phase              | Primary purpose | Summary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                              |
|-------|-------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|-------------|---------------------------------------------------------------------------------------------------|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------|------------------|--------------------|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|       |                               |                                                                                                                                                                                       |                       |             |                                                                                                   |                 |                                                                                                                                            | Treatment group                                                                                                  | Comparison group |                    |                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                              |
| 1     | NCT00531862                   | A RUC-2/Cetuximab Trial in a PC1 Inhibitor With or Without a Vitamin D Analog for the Maintenance of Pancreatic Cancer                                                                | 2017-12-27-2020-06-29 | Germany     | Randomized, Parallel Assignment, Quadruple (Participant, Care Provider, Investigator, Datacenter) | 28              | Pancreatic Cancer, Pancreas Adenocarcinoma, Advanced Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma | Drug: Pembrolizumab, Drug: metformin                                                                             | Drug: placebo    | Phase 2            | Treatment       | The study is being conducted to determine the efficacy that pembrolizumab with or without the addition of metformin may have on pancreatic cancer. Half of the patients will be randomized to receive pembrolizumab + metformin and half to receive pembrolizumab + placebo.                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                              |
| 2     | NCT01168119                   | Olaparib (OPV-102) Alone and in Combination With Pembrolizumab in Colorectal and Pancreatic Cancer                                                                                    | 2017-04-19-2020-03-23 | Germany     | N.S. Single-Group Assignment, None (Open Label)                                                   | 28              | Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer                                                                                 | Drug: Olaparib oral ; Monotherapy, Drug: Olaparib oral + Pembrolizumab ; Combination Therapy                     | NO               | Phase 1<br>Phase 2 | Treatment       | The purpose of this study is to show that the type, number and/or distribution of tumor mutations influencing immune cells such as cytotoxic T cells and/or the cytokine signature in the tumor microenvironment can be modulated by treatment with olaparib ppa and to explore safety, tolerability and efficacy of olaparib ppa in combination with pembrolizumab as a basis for subsequent studies in combination with immunotherapies, in particular, checkpoint inhibitors.                                                        |                                                                                                                                                                                                                                                                                                              |
| 3     | NCT02737710                   | Evaluation of Safety and Activity of an Anti-PDL1 Antibody (DURVALUMAB) Combined With CTR-01-TR1 (PENCIMUTINIB) in Patients With Metastatic/Advanced Pancreatic or Colorectal Cancers | 2018-06-2019-11       | France      | N.S. Single-Group Assignment, None (Open Label)                                                   | 38              | Colorectal Cancer, Pancreatic Cancer, Metastatic Cancer, Advanced Cancer                                                                   | Drug: Pembrolizumab, Drug: Durvalumab                                                                            | NO               | Phase 1            | Treatment       | This study is to conduct a Phase I dose escalation study in order to evaluate the safety and clinical activity of a combined treatment associating an anti-CTR-1(PENCIMUTINIB) with an anti-PDL1 (DURVALUMAB) in patients with advanced/metastatic colorectal or pancreatic cancers. Dose escalation part will determine the Maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of Pembrolizumab given in combination with Durvalumab. Extension part will evaluate the clinical activity of the combination at the RP2D. |                                                                                                                                                                                                                                                                                                              |
| 4     | NCT02179970                   | To Assess the Safety of Continuous IV Administration of Placebo in Patients With Advanced/Pancreatic, Ovarian and Colorectal Cancers                                                  | 2015-06-2018-12-14    | France      | N.S. Single-Group Assignment, None (Open Label)                                                   | 26              | Pancreatic Adenocarcinoma Metastatic, Ovarian Serous Adenocarcinoma, Colorectal Cancer Metastatic                                          | Drug: Placebo                                                                                                    | NO               | Phase 1            | Treatment       | The purpose of this study is to find out if the study drug has the same effect on patients with advanced pancreatic, ovarian or colorectal cancer, as they have seen in our laboratory experiments, and find out the right dose of the study drug to give.                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                              |
| 5     | NCT02090600                   | A Randomized/Placebo/Pharmacodynamic/Genomic Study of Neoadjuvant Pembrolizumab to Target the Microenvironment in Resectable Pancreatic Cancer                                        | 2016-01-2019-12       | USA         | Randomized, Parallel Assignment, None (Open Label)                                                | 11              | Adenocarcinoma of the Pancreas                                                                                                             | Drug: Pembrolizumab, Drug: Abiraterone, Drug: Gemtuzumab                                                         | NO               | Not Applicable     | Treatment       | This study is a randomized pilot/pharmacodynamic/genomic study of neoadjuvant pembrolizumab to target the microenvironment in resectable pancreatic cancer to determine the effect of targeting the vitamin D metabolic program in the tumors of patients treated with one cycle of gemtuzumab/abiraterone with or without pembrolizumab prior to surgery for resectable pancreatic cancer through an assessment of cellular and immune markers.                                                                                        |                                                                                                                                                                                                                                                                                                              |
| 6     | NCT01999000                   | The Role of the Tumor Microenvironment of Pancreatic Cancer to Predict Treatment Outcome                                                                                              | 2013-11-2017-12       | Netherlands | Non-Randomized, Parallel Assignment, None (Open Label)                                            | 87              | Pancreatic Cancer                                                                                                                          | Drug: Gemtuzumab, Drug: [P-18]DCA, Drug: Gemtuzumab, Radiation: Radiotherapy, Procedure: Pancreaticoduodenectomy | NO               | Not Applicable     | Diagnostic      | The study is to use tumor cellularity and extracellular matrix composition to assess tumor invasively in vivo by diffusion-weighted magnetic resonance imaging (DWI) and tumor vascularity can be assessed by dynamic contrast enhanced magnetic resonance imaging (DCE-MRI). Tumor hypoxia can be evaluated by T2* MRI and PET-CT, using the 18F-labeled hypoxia marker H2O.                                                                                                                                                           |                                                                                                                                                                                                                                                                                                              |
| 7     | NCT01905831                   | Chemotherapy and Radiation in Pancreatic Cancer                                                                                                                                       | 2013-07-2017-12       | USA         | N.S. Single-Group Assignment, None (Open Label)                                                   | 18              | Locally Advanced/Malignant Neoplasm                                                                                                        | Drug: Taxolab, Drug: Gemtuzumab, Radiation: Radiation, Procedure: Pancreaticoduodenectomy                        | NO               | Phase 1            | Treatment       | The goal of this study is to evaluate the safety of combination treatment that includes chemotherapy, radiation therapy, and immunotherapy in patients with pancreatic cancer.                                                                                                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                                                              |
| 8     | NCT01708142                   | Effect on Tumor Perfusion of a Chemotherapy/Combining Gemtuzumab and Nalpegitide (Abiraterone) in Pancreatic Cancer                                                                   | 2013-03-21-2015-09-21 | USA         | N.S. Single-Group Assignment, None (Open Label)                                                   | 20              | Pancreatic Adenocarcinoma Resectable, Pancreatic Adenocarcinoma Locally Advanced, Pancreatic Adenocarcinoma Metastatic                     | Drug: Gemtuzumab, Drug: Abiraterone                                                                              | NO               | Early Phase 1      | Treatment       | This proof of concept trial is studying the "dynamic" tumor response after the administration of a short course of gemtuzumab and nalpegitide (Abiraterone) (a) during a window interval (a window-1 cycle) before surgery in resectable pancreatic cancer (cohort 1 = 20 patients) and (b) during at least 8 weeks (2 cycles) in locally advanced or metastatic pancreatic cancer (cohort 2 = 10 patients).                                                                                                                            |                                                                                                                                                                                                                                                                                                              |
| 9     | NCT00804911                   | Role of CXCR2 Ligand/CXCR2 Biological Axis in Pancreatic Cancer                                                                                                                       | 2007-08-2009-12       | USA         | Case Only, Prospective                                                                            | 100             | Chronic Pancreatitis, Pancreatic Cancer                                                                                                    |                                                                                                                  |                  |                    |                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | The investigators hypothesize that the CXCR2 ligand/CXCR2 biological axis plays an important role in promoting angiogenesis in PC, and that the genetic changes and the microenvironment of the tumor regulate the expression of CXCR2 ligand/CXCR2 in PC in order to potentiate their angiogenic phenotype. |